A consultation with our medical team is required to determine if these therapies are appropriate for you.
In future development, we will continue to adhere to our original management tenet, insist on technological innovation and service upgrading, and keep improving product competitiveness and market adaptability
En un comunicado de prensa, Teva Pharmaceuticals anunci que la FDA aprob y lanz la primera versin genrica de liraglutida indicada para prdida de peso
Dapagliflozin reduced the primary composite outcome (sustained 50% eGFR decline, ESKD, or death from renal or cardiovascular causes) by 39% compared to placebo [47]
LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
Key Clinical Significance Succinylcholine-induced hyperkalemia is most dangerous in patients with: Major burns Neuromuscular disorders (e.g., Duchenne or Becker muscular dystrophy) Severe trauma with muscle injury Prolonged immobilization Significant denervation injuries Because of the risk of fatal cardiac arrhythmias, succinylcholine should be avoided in these high-risk populations , and alternative neuromuscular blocking agents such as rocuronium are often preferred (Hovgaard & Juhl-Olsen, 2021